In 2018, Gao et al. applied CRISPR/Cas9-based treatment in vivo to achieve (transmembrane channel-like gene family 1) (Tmc1) allele gene disruption in a Beethoven (Tmc1Bth/+) mouse model of a human genetic HL, leading to the amelioration of a disease phenotype [112], which further shows the potential of CRISPR/Cas-mediate treatment for genetic HL. Here, TMC1 is linked to Hodgkins lymphoma.